Cue Biopharma, Inc.

CUE Nasdaq SEC CIK 1645460
Follow Cue Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $132K −93.9% vs same quarter last year
Net income −$50M −571.5% vs same quarter last year
EPS, diluted −$4.74 −113.5% vs same quarter last year
Operating cash flow −$10.1M −11.7% vs same quarter last year
Revenue by quarter
$1.6M
$421K
$3M
$2.1M
$21.9M
$5.7M
$7.9M
$132K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25M$50MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$27.5M−$26.6M
FY24$9.3M−$40.7M
FY23$5.5M−$50.7M
FY22$1.2M−$53M
FY21$14.9M−$44.2M
FY20$3.2M−$44.8M
FY19$3.5M−$36.7M
FY18$1.1M−$39M
FY17-−$23.2M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−96.7%−96.9%
FY24−446.9%−438%
FY23−949.9%−924.1%
FY22−4275.1%−4257.8%
FY21−292.6%−295.6%
FY20−1428%−1419.8%
FY19−1063.2%−1061.2%
FY18−3386.7%−3411.5%
FY17--
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$21.9M
FY24−$36.4M
FY23−$40M
FY22−$42M
FY21−$39.8M
FY20−$33.1M
FY19−$30.8M
FY18−$28.3M
FY17−$13.2M
FY16-
Returned to shareholdersDividends paid and shares bought back
$0$200K$400K$600K$800KFY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25-
FY24-
FY23$0
FY22$200K
FY21$750.1K
FY20$271.1K
FY19$91K
FY18-
FY17-
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Cue Biopharma
  • Healthcare median
−6000%−4000%−2000%0%FY17FY19FY21FY23FY25
Show the numbers
YearCue BiopharmaHealthcare median
FY25−96.9%−30.6%
FY24−438%−47%
FY23−924.1%−58%
FY22−4257.8%−80.4%
FY21−295.6%−71.9%
FY20−1419.8%−62.2%
FY19−1061.2%−46.3%
FY18−3411.5%−49.6%
FY17-−45.9%
FY16-−36%